Please login to the form below

Not currently logged in
Email:
Password:

Watson expands in Europe with Specifar deal

Watson Pharmaceuticals has acquired Greece-based Specifar Pharmaceuticals, the generic pharmaceutical developer, manufacturer and marketer for €400m ($562m)

Watson Pharmaceuticals has acquired Greece-based Specifar Pharmaceuticals, the generic pharmaceutical developer, manufacturer and marketer for €400m ($562m).

The acquisition adds to Watson's commercial presence in key European markets by providing a portfolio of approved products. The transaction also gives Watson a strong branded-generic commercial presence in the Greek pharmaceutical market.

Specifar's pipeline includes a generic tablet version of Nexium (esomeprazole), which could launch in certain European markets as early as the fourth quarter of 2011. Under the terms of the acquisition agreement, Specifar's former owners could receive additional consideration based on future profits from this product.

Paul Bisaro, Watson's president and chief executive, said: "The strategic significance of this combination is substantial. Watson will now have a powerful product development capability recognised throughout the industry for its strong track record of successfully launching products in key European markets, supported by an accomplished R&D and regulatory capability.

He continued: "The development business will continue to develop and market products to third parties under the Specifar name and now will also develop products for Watson's commercial groups worldwide. In addition, we intend to expand Specifar's development capabilities and create a centre of excellence for product development in international markets. We also believe that Specifar's European management expertise and existing business relationships will support Watson's current and future commercial expansion in European countries."

The Specifar group is in the top five in the Greek branded-generic market, with a portfolio of more than 30 products. It also markets products in Greece under the Alet Pharmaceuticals brand through a separate sales force.

26th May 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics